- Home
- DGNX vs AMPH Comparison
DGNX vs AMPH Comparison
Compare DGNX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGNX
- AMPH
- Stock Information
- Founded
- DGNX 2018
- AMPH 1996
- Country
- DGNX United Kingdom
- AMPH United States
- Employees
- DGNX N/A
- AMPH N/A
- Industry
- DGNX
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- DGNX
- AMPH Health Care
- Exchange
- DGNX NYSE
- AMPH Nasdaq
- Market Cap
- DGNX 1.2B
- AMPH 1.3B
- IPO Year
- DGNX 2025
- AMPH 2014
- Fundamental
- Price
- DGNX $115.10
- AMPH $23.35
- Analyst Decision
- DGNX
- AMPH Hold
- Analyst Count
- DGNX 0
- AMPH 3
- Target Price
- DGNX N/A
- AMPH $43.50
- AVG Volume (30 Days)
- DGNX 50.7K
- AMPH 745.5K
- Earning Date
- DGNX 01-01-0001
- AMPH 05-07-2025
- Dividend Yield
- DGNX N/A
- AMPH N/A
- EPS Growth
- DGNX N/A
- AMPH 17.69
- EPS
- DGNX N/A
- AMPH 3.06
- Revenue
- DGNX $1,177,066.00
- AMPH $731,967,000.00
- Revenue This Year
- DGNX N/A
- AMPH $2.15
- Revenue Next Year
- DGNX N/A
- AMPH $6.64
- P/E Ratio
- DGNX N/A
- AMPH $7.63
- Revenue Growth
- DGNX N/A
- AMPH 13.59
- 52 Week Low
- DGNX $3.60
- AMPH $22.74
- 52 Week High
- DGNX $155.00
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- DGNX N/A
- AMPH 32.78
- Support Level
- DGNX N/A
- AMPH $22.64
- Resistance Level
- DGNX N/A
- AMPH $24.92
- Average True Range (ATR)
- DGNX 0.00
- AMPH 1.29
- MACD
- DGNX 0.00
- AMPH -0.22
- Stochastic Oscillator
- DGNX 0.00
- AMPH 10.71
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.